- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01055535
Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion (MIVI-8)
An Open Label, Single Centre Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
- University Hospital Leuven
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- I. Male or female patients aged > 18
- II. Presence of focal vitreomacular adhesion (ie, central vitreal adhesion within 6mm OCT field surrounded by elevation of the posterior vitreous cortex
- III. BCVA of 20/32 or worse in the study eye
- IV. BCVA of 20/400 or better in the contralateral eye
- V. Written informed consent obtained from the patient prior to inclusion in the study
Exclusion Criteria:
- I. Evidence of complete macular PVD in the study eye on biomicroscopy, B-scan or OCT prior to planned study drug injection
- II. Any evidence of proliferative retinopathy meeting the definition for PDR in the study eye
- III. Patients with vitreous hemorrhage which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiogram in the study eye
- IV. Patients with rhegmatogenous retinal detachment, PVR, or retinal degenerative changes associated with increased risk of retinal detachment in the study eye. Such retinal degenerative changes include lattice degeneration or cystic retinal tufts. Thorough retinal examination should be performed in all patients to rule out these changes.
- V. Patients with high myopia (> 8D) or aphakia in the study eye
VI. Patients with history of rhegmatogenous retinal detachment in the fellow eye VII. Patients who have had ocular surgery in the study eye in the prior three months VIII. Patients who have had a vitrectomy in the study eye at any time. IX. Patients with glaucoma that is not controlled with topical medication or that is associated with severe visual field loss, documented by perimetry, in the study eye X. Patients who have had laser photocoagulation treatment in the study eye in the previous 3 months XI. Intravitreal injection of any drug in the study eye in the previous 3 months XII. Patients who are pregnant or of child-bearing potential not utilizing a form of contraception acceptable to the Investigator XIII. Patients who, in the investigators view, will not complete all visits and investigations, including the last visit at 6 months after the last injection XIV. Patients who have participated in an investigational drug study within the past 30 days XV. Patients with hypertension (either SBP > 170 or DBP > 100 mm Hg) XVI. Patients with a life expectancy less than 6 months XVII. Patients who have previously participated in this trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Microplasmin
|
125 µg intravitreal injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
History/full ophthalmologic examination (including full retinal examination: baseline, post-injection days 7, 14 and 28 and months 3 and 6
Time Frame: baseline, day 7, 14 and 28 and months 3 and 6
|
baseline, day 7, 14 and 28 and months 3 and 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with nonsurgical resolution of focal vitreomacular adhesion at study visits other than the 28 day post-injection visit
Time Frame: Day 28
|
Day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TG-MV-008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Focal Vitreomacular Adhesion
-
Allegro Ophthalmics, LLCCompletedSymptomatic Focal Vitreomacular AdhesionUnited States
-
Jeffrey S HeierKato Pharmaceuticals, Inc.CompletedVitreomacular Traction | Vitreomacular Adhesion | Vitreomacular AttachmentUnited States
-
Alcon ResearchCompletedVitreomacular Traction | Vitreomacular AdhesionAustralia
-
Alcon ResearchCompletedVitreomacular Traction | Vitreomacular Adhesion
-
ThromboGenicsCompletedVitreomacular AdhesionUnited States
-
ThromboGenicsCompletedVitreomacular AdhesionUnited States, Spain, United Kingdom, Germany, Belgium, Czech Republic, Poland
-
ThromboGenicsCompletedExudative Age-Related Macular Degeneration | Focal Vitreomacular AdhesionUnited States, United Kingdom, Germany, France, Belgium, Italy
-
ThromboGenicsCompletedSymptomatic Vitreomacular AdhesionUnited States
-
ThromboGenicsCompletedSymptomatic Vitreomacular AdhesionUnited States, Belgium
-
Nova Southeastern UniversityThromboGenics; Optovue; Carl Zeiss Meditec, Inc.CompletedVitreomacular AdhesionUnited States
Clinical Trials on Microplasmin
-
ThromboGenicsTerminated
-
National Institutes of Health Clinical Center (CC)National Eye Institute (NEI)Terminated
-
ThromboGenicsBacchus VascularTerminatedDeep Vein ThrombosisIreland
-
ThromboGenicsCompletedEye Diseases | Vitreomacular Traction MaculopathyBelgium, Netherlands
-
ThromboGenicsTerminatedArterial Occlusive DiseasesBelgium
-
ThromboGenicsCompletedVitreomacular AdhesionUnited States, Spain, United Kingdom, Germany, Belgium, Czech Republic, Poland
-
ThromboGenicsCompleted
-
ThromboGenicsCompletedStroke, AcuteGermany, Belgium, Austria
-
University of California, Los AngelesThromboGenicsUnknownMacular DegenerationUnited States
-
ThromboGenicsCompletedVitreomacular AdhesionUnited States